Becker's Healthcare January 24, 2025
Alexandra Murphy

AbbVie has entered a collaboration with Neomorph to develop molecular glue degraders for oncology and immunology.

Molecular glue degraders are a class of small molecules designed to selectively degrade proteins that contribute to disease, including those involved in cancer growth and immune system dysfunction, according to a Jan. 23 news release from the drugmaker.

...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Pharma / Biotech
Pharma Dodges The Tariff Bullet — But For How Long?
Noom, LillyDirect pharmacy provider partner to increase access to Zepbound
PBM Private Labeling Boosts Biosimilars, Raises Concerns
Q&A: How can drug repurposing lower drug costs and improve care?
BC researchers receive $49M for genomics projects

Share This Article